SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Innodata, Inc. is a data engineering company, which engages in providing artificial intelligence software platforms and management of its services. It operates through the following business segments: Digital Data Solutions (DDS), Synodex, and Agility. The DDS segment combines deep neural networks and human expertise in multiple domains to make unstructured information useable. The Synodex segment enables clients in the insurance and healthcare sectors to transform medical records into useable digital data and to apply technologies to the digital data to augment decision support. The Agility segment provides tools and related professional services that enable public relations and communications professionals to discover influencers, amplify messages, monitor coverage, and measure the impact of campaigns. The company was founded by Todd H. Solomon in 1988 and is headquartered in Ridgefield Park, NJ.

Innodata Inc

Innodata is trending following its new partnership with Palantir, which the community widely interprets as a strategic entry into high-value government and military AI data engineering, building on recent defense contract wins. Bulls are highlighting the company's crucial role in providing human-verified data to combat AI data quality issues, driving optimism for significant growth and a potential short squeeze ahead of anticipated strong earnings.

TOYO Co. Ltd. engages in the design, manufacture, and sale of solar cells and modules. It is involved in integrating the upstream production of wafer and silicon, midstream production of solar cell, downstream production of photovoltaic (PV) modules, and potentially other stages of the solar power supply chain. The company was founded on November 8, 2022 and is headquartered in Tokyo, Japan.

TOYO Co Ltd.

TOYO Co., Ltd

TOYO is trending after a major lawsuit threatening its US operations was dismissed, removing a legal overhang as the company announced a significant $150 million contract and its Houston facility began commercial production. The community highlights TOYO's extreme undervaluation with strong growth projections and increasing institutional interest, anticipating a substantial re-rating.

Coeptis Therapeutics Holdings, Inc. is a biopharmaceutical company, which engages in developing innovative cell therapy platforms for cancer that can disrupt conventional treatment paradigms and improve patient outcomes. It operates through the Biotechnology and Technology segments. The Biotechnology segment is involved in developing biotechnology product pipelines. The Technology segment relates to acquiring technology assets to support and enhance operational capabilities through advanced technologies. The company was founded in 2017 and is headquartered in Wexford, PA.

Coeptis Therapeutics Holdings Inc

Coeptis Therapeutics Inc

Coeptis Therapeutics is trending due to its impending strategic merger with Z Squared, a Dogecoin and Litecoin mining company, marking a significant pivot from its biopharmaceutical roots. The community eagerly anticipates the shareholder vote and merger completion, expecting a substantial re-valuation and potential short squeeze driven by the new entity's crypto mining operations and its perceived low float.

Ripple is the catchall name for the cryptocurrency platform, the transactional protocol for which is actually XRP, in the same fashion as Ethereum is the name for the platform that facilitates trades in Ether. Like other cryptocurrencies, Ripple is built atop the idea of a distributed ledger network which requires various parties to participate in validating transactions, rather than any singular centralized authority. That facilitates transactions all over the world, and transfer fees are far cheaper than the likes of bitcoin. Unlike other cryptocurrencies, XRP transfers are effectively immediate, requiring no typical confirmation time.  Ripple was originally founded by a single company, Ripple Labs, and continues to be backed by it, rather than the larger network of developers that continue bitcoin’s development. It also doesn’t have a fluctuating amount of its currency in existence. Where bitcoin has a continually growing pool with an eventual maximum, and Ethereum theoretically has no limit, Ripple was created with all of its 100 billion XRP tokens right out of the gate. That number is maintained with no mining and most of the tokens are owned and held by Ripple Labs itself — around 60 billion at the latest count.  Even at the recently reduced value of around half a dollar per XRP, that means Ripple Labs is currently sitting on around $20 billion worth of the cryptocurrency (note: Ripple’s price crashed hard recently, and may be worth far less than $60 billion by time you read this). It holds 55 billion XRP in an escrow account, which allows it to sell up to a billion per month if it so chooses in order to fund new projects and acquisitions. Selling such an amount would likely have a drastic effect on the cryptocurrency’s value, and isn’t something Ripple Labs plans to do anytime soon.  In actuality, Ripple Labs is looking to leverage the technology behind XRP to allow for faster banking transactions around the world. While Bitcoin and other cryptocurrencies are built on the idea of separating financial transactions from the financial organizations of traditional currencies, Ripple is almost the opposite in every sense.  XRP by Ripple price can be found on this page alongside the market capitalization and additional stats.

Ripple

XRP is trending amid a broader crypto market downturn and a sharp divergence in community sentiment, following news of the Senate Agriculture Committee advancing a crypto market structure bill. Investors are debating whether current price dips are a strategic "shakeout" before anticipated regulatory clarity and institutional adoption, or a reflection of underlying project flaws and market manipulation.

Oxford Lane Capital Corp. is a closed-end management investment company, which engages in investing in debt and equity tranches of collateralized loan obligation vehicles. The company was founded on June 9, 2010 and is headquartered in Greenwich, CT.

Oxford Lane Capital Corp

Oxford Lane Capital Corp. is trending sharply lower after announcing a significant dividend reduction and a substantial drop in its net asset value (NAV), igniting widespread shareholder frustration and questions about management's strategy. This move, intended by the board to stabilize the portfolio amid a challenging Collateralized Loan Obligation (CLO) market, has sharply divided the community between those exiting the stock and those hoping for long-term recovery.

Newegg Commerce, Inc. is an e-commerce company. It offers direct sales and an online marketplace platform for IT computer components, consumer electronics, entertainment, smart home and gaming products. The firm also provides third-party logistics services globally. The company was founded on July 22, 2003 and is headquartered in City of Industry, CA.

Newegg Commerce Inc

Newegg Commerce is experiencing significant price volatility following news of its Chairman's detention in China, though many in the community view this as a market manipulation tactic. Investor Vlad Galkin's continuous share accumulation, which has reportedly locked up the float, is fueling intense discussion about massive naked shorting and the potential for a substantial squeeze, with some speculating about a GameStop acquisition.

Ulta Beauty, Inc. engages in the retail of beauty products. The company has one reportable segment, which includes retail stores, salon services, and e-commerce. Its products include makeup, skin care, tools and brushes, fragrance, and bath and body. The company was founded on January 9, 1990 and is headquartered in Bolingbrook, IL.

Ulta Beauty Inc

Ulta Beauty is soaring on the heels of a robust Q3 earnings beat and raised full-year guidance, propelling the stock to new all-time highs while the community actively debates the sustainability of its momentum given resilient consumer spending in the beauty sector.

Unity Software, Inc. engages in the developing video gaming software. It also provides software solutions to create, run and monetize interactive, real-time two-dimensional and three-dimensional content for mobile phones, tablets, consoles, and augmented and virtual reality devices. Its platform is used by developers, artists, and designers to build content for gaming, film, retail, automotive, architecture, engineering, and construction industries. The company was founded by Joachim Ante and David Helgason in 2004 and is headquartered in San Francisco, CA.

Unity Software Inc

Unity Software is experiencing a significant sell-off following Google's introduction of Project Genie, an AI tool capable of generating 3D virtual worlds from text prompts. While some investors fear this AI could render traditional game engines obsolete, others are calling it an overreaction and a buying opportunity, with Unity's CEO suggesting it could accelerate their own AI-driven development.

Vanguard Group, Inc. - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending amid record ETF inflows, reflecting strong investor demand for broad market exposure. The community is actively debating the market's trajectory, influenced by upcoming Federal Reserve decisions and progress on government funding, alongside concerns about the sustainability of current large-cap valuations.

Adlai Nortye Ltd. is a clinical-stage biopharmaceutical company, which engages in the provision of development of cancer therapies for patients with stages of tumors. It offers AN0025, a clinical stage, potential EP4 antagonist designed to modulate tumor microenvironment. The company was founded on May 9, 2018, and is headquartered in Hangzhou, China.

Adlai Nortye Ltd. - ADR

Adlai Nortye Ltd. American

Adlai Nortye (ANL) is trending following an exclusive licensing agreement with ASK Pharm for its AN9025 cancer drug in Greater China, a deal valued at up to $230 million. The community is buzzing with excitement over the significant cash injection and speculating on a potential sustained rally, comparing it to other recent low-float runners.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

FOLD vs. RIGL: Which Rare Disease Biotech Stock Has Better Upside?

Amicus and Rigel target rare diseases, but a pending BioMarin buyout and growing drug sales set up different upside paths for investors.

Best Biotech Stocks To Follow Now - January 26th

Danaher, Moderna, Vertex Pharmaceuticals, ImmunityBio, argenex, Amicus Therapeutics, and BioNTech are the seven Biotech stocks to watch today, according to MarketBeat's stock screener tool. Biotech...

Amicus Therapeutics, Inc. (NASDAQ:FOLD) Given Consensus Rating of "Hold" by Brokerages

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) has been assigned an average recommendation of "Hold" from the fourteen analysts that are covering the firm, Marketbeat.com reports. One...

FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders

Halper Sadeh LLC, an investor rights law firm, is investigating whether the sale of Amicus Therapeutics, Inc. (NASDAQ: FOLD) to BioMarin Pharmaceutical Inc. for $14.50 per share is fair to Amicus...

JANX Enters Global Oncology Collaboration With BMY, Stock Rises

Janux Therapeutics struck a global licensing deal for its tumor-activated platforms, sending shares higher and expanding its reach in solid tumors.

Amicus Therapeutics (NASDAQ:FOLD) CEO Bradley Campbell Sells 75,000 Shares

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 75,000 shares of the firm's stock in a transaction dated Tuesday, January 20th. The shares were sold at an average...

Bradley Campbell Sells 75,000 Shares of Amicus Therapeutics (NASDAQ:FOLD) Stock

Amicus Therapeutics, Inc. (NASDAQ:FOLD - Get Free Report) CEO Bradley Campbell sold 75,000 shares of Amicus Therapeutics stock in a transaction dated Tuesday, January 20th. The stock was sold at an...

Ionis' Dawnzera Gets EU Approval for Hereditary Angioedema

IONS secures EU approval for Dawnzera in hereditary angioedema, after FDA clearance in the United States in August last year.

ImmunityBio Stock Soars on FDA Talks for Anktiva sBLA Resubmission

IBRX stock jumps 17% after FDA talks outline the path to resubmit Anktiva sBLA for papillary NMIBC, with additional analyses done and filing planned soon.

NVO Expands Aspect Tie-Up to Advance Curative Diabetes Cell Therapies

Novo Nordisk deepens its alliance with Aspect Biosystems to develop next-generation, potentially curative cell therapies for diabetes, aiming to achieve long-term upside.

Amicus Therapeutics, Inc. is a biotechnology company, which focuses on discovering, developing, and delivering medicines for people living with metabolic diseases. Its product portfolio includes first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants, a novel, clinical-stage, treatment paradigm for Pompe disease and a rare disease gene therapy portfolio. The company was founded by John Francis Crowley on February 4, 2002 and is headquartered in Princeton, NJ.

FOLD
Amicus Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest FOLD News

FOLDAmicus Therapeutics Inc